BOZEMAN, Mont. -- Researchers at Montana State University have developed six new biomedical technologies that could have applications for treating antibiotic resistant infections, fungal infections and viral infections; boosting humans' innate immunity and improving scientists' ability to study such compounds.
The technologies are available for licensing to interested companies and entrepreneurs.
The first technology involves an existing clinical drug that was discovered to act as a potent trigger of immune cells. In this role, it could enhance the effectiveness of antibiotics in treating bacterial infections such as Staphylococcus aureus, particularly antibiotic-resistant staph infections.
The drug also shows promise in enhancing the effectiveness of vaccines, particularly those administered to the lungs. The drug is fully approved and commercially available and could be used as a stand-alone therapy or used in combination with other existing antibiotics or vaccines to increase their value. A patent is pending, and the research is ongoing.
The second technology is an extract from a plant commonly known as Fireweed. Epilobium angustifolium produces a compound, oenothein B, which is recognized for its antioxidant, antitumor, antibacterial and antiviral properties. Until now, only limited evidence showed that this compound enhances innate immunity.
MSU research discovered the extract has the potential to bolster the human immune system by activating a number of mechanisms of important disease-fighting cells in the body, phagocytes. Phagocytes have the ability to envelop and devour harmful bacteria, parasites and other substances, and destroy them through a variety of means.
Potential applications of the extract include increasing immunity during bio-warfare threats, flu epidemics, or for travelers who will be exposed to endemic diseases. Benefits of the extract include its potential to rapidly trigger th
|Contact: Evelyn Boswell|
Montana State University